India Concentration

One market carries the top line

India was 8.9% of Herbalife's net sales in 2021 and 20.9% in the March 2026 quarter. Everything else, taken together, has shrunk 21.5% over that span. India's step-change arrived in the quarter after the Indian government cut GST on most of the company's products from 18% to 5%, effective 22 September 2025. That tax change lowered Indian shelf prices, carries a recurring cost to Herbalife, and annualises in September 2026.

Where the growth actually is

Herbalife's consolidated net sales fell from $5,802.8 million in 2021 [1] to $5,037.5 million in 2025 [2]. Inside that decline, one market went the other way: India rose from $519.1 million to $889.6 million [3] [4], an increase of $370.5 million, or 71.4%. The rest of the company fell from $5,283.7 million to $4,147.9 million, a decline of $1,135.8 million, or 21.5%; over the shorter 2023–2025 window the same base fell 2.8%, from $4,265.8 million.

Sources: India net sales from the FY2021 [5], FY2022 [6], FY2023 [7], FY2024 [8] and FY2025 [9] Form 10-Ks; rest of company derived as consolidated net sales less India, consolidated figures per the FY2021 [10], FY2023 [11] and FY2025 [12] Form 10-Ks.

The 2025 arithmetic makes the dependence exact. Consolidated net sales rose $44.4 million, or 0.9% [13]. India rose $44.8 million [14]. In local currency the picture is less absolute but still lopsided: consolidated local-currency net sales rose 2.5%, about $124.8 million, of which India's 9.7% gain on an $844.8 million base contributed roughly $81.9 million — two-thirds of the total.

The March 2026 quarter tightened it further. Consolidated net sales were $1,317.2 million, up $95.5 million or 7.8%, and up 5.4% in local currency [15]. India was $275.4 million of that, up $66.1 million reported and up 39.0% in local currency against a $15.5 million currency headwind — an $81.6 million local-currency increase [16]. The company's own bridge puts total local-currency net sales at $1,288.1 million against $1,221.7 million, a $66.4 million increase [17]. India therefore contributed more local-currency growth than the company as a whole produced: outside India, local-currency net sales were roughly $15 million lower than a year earlier, about 1.5% down on a $1,012 million base.

Sources: Q1 2026 Earnings Presentation, Regional Net Sales [18]; regional volume and India detail from the Q1 2026 earnings call [19] [20] and the Q1 FY2026 Form 10-Q [21] [22].

Asia Pacific was the only region with volume growth in the quarter. Latin America's 7% local-currency gain came with volume down 2%, and EMEA's 11% volume decline outweighed its pricing [23]. Within Asia Pacific, India's $81.6 million local-currency increase accounts for roughly 93% of the region's $88 million gain, leaving the rest of Asia Pacific up about 3%.

A tax change with a date on it

India's acceleration is not a gradual trend. Quarterly net sales sat in a $178 million to $226 million band for eleven straight quarters, then stepped to $250.3 million and $275.4 million.

Sources: quarterly India net sales per Form 10-Q filings — Q2 FY2023 [24], Q3 FY2023 [25], Q1 FY2024 [26], Q2 FY2024 [27], Q3 FY2024 [28], Q1 FY2025 [29], Q2 FY2025 [30], Q3 FY2025 [31] and Q1 FY2026 [32]; the first quarter of 2023 derived as the six months ended June 30, 2023 less the June quarter, and fourth-quarter figures derived as full-year net sales less the corresponding nine months, full-year figures per the FY2023 [33], FY2024 [34] and FY2025 [35] Form 10-Ks.

The break coincides with a specific date. Effective 22 September 2025 the Indian government reduced GST rates across multiple sectors, cutting the rate on the majority of Herbalife's products sold to members from 18% to 5% [36]. GST is a pass-through tax collected on top of the company's own price, so the change moved the shelf price without moving what Herbalife realises per unit: a tax-inclusive price falls 11.0% when the rate goes from 18% to 5%, and the corresponding cut in maximum retail price for Indian nutraceuticals was put at about 11.1%, with the government pressing manufacturers to pass the saving through in full.

That is why India's volume and its local-currency net sales move together. Herbalife took no price increase in India during 2025 or the March 2026 quarter — the last was 3.0% in November 2024 [37] [38]. India volume rose 6.8% across 2025, with the tax cut live for only the final fourteen weeks [39], then 36.9% in the March 2026 quarter [40]. Management has been direct about the mechanism: the fourth-quarter record of roughly $250 million was "fueled by stronger demand following the reduction of the goods and services tax rate" [41], and on the March quarter call the CFO put it plainly: "We had effectively a price decrease due to the GST reduction, and that created a lot of momentum" [42].

An 11% consumer price cut associated with a 37% volume response implies demand elasticity around three — high for a nutrition brand, and a useful data point about how the Indian member base actually converts price into units. The company has drawn the same conclusion and intends to test it elsewhere: "there is a lot of opportunity for us to affect volume in the future by modifying price and modifying the commission structure" [43]. The mechanism does not transfer to the rest of the portfolio unchanged. In India the government funded the discount out of tax, leaving Herbalife's gross margin per unit intact; a price cut made by Herbalife in another market would reduce a 77.9% gross margin [44].

What the tax cut costs

The rate cut applies to products, not services. The GST charged on services provided by distributors and on intercompany services stayed at 18%, so the input credits Herbalife used to offset can no longer be absorbed [45]. Three consequences show up in the accounts.

Sources: transition charge per the FY2025 Form 10-K [46]; FY2026 cost guidance of $20–25 million per the Q1 2026 earnings call [47]; recognised credits per the Q1 FY2026 Form 10-Q [48].

First, a one-time write-off. The FY2025 accounts carry an $11.3 million pre-tax ($8.5 million post-tax) transition charge for credits generated before the law changed [49], excluded from adjusted EBITDA [50].

Second, a recurring cost that scales with India's success. In February 2026 management sized the 2026 impact at about $16 million and roughly 30 basis points of margin [51]. Eleven weeks later, "based on India's first quarter sales performance and our outlook for the balance of the year", the estimate rose to $20–25 million and 40–50 basis points [52]. Against full-year adjusted EBITDA guidance of $675–705 million [53], that is roughly 3% to 3.6% of the midpoint, and it grows as India grows. Herbalife has offset part of it in a way that connects directly to the network economics examined in Sales Leader Turnover: it cut the sales commission percentage paid to its distributors, booked in selling expenses [54]. The market Herbalife most depends on for growth is also the one where the payout rate has been reduced.

Third, an asset that is not on the balance sheet. Excess GST input credits have accumulated since the September 2025 amendments, and Herbalife states that it "does not expect to generate sufficient future GST liabilities to utilize all of these GST input credits, and the likelihood of receiving a cash refund for certain credits remains uncertain; accordingly, no asset has been recognized" [55]. Only about $10 million was carried as a current asset at 31 March 2026, up from about $5 million three months earlier, covering the portion judged reasonably assured of refund [56] [57]. The company intends to pursue recovery, possibly through litigation, with the outcome uncertain [58]. This is the conservative treatment — the expense runs through earnings while no receivable is booked — which means the guided $20–25 million is a real drag rather than a reserve that can be released.

The September comparison

Management has set out the sequence itself. The GST tailwind is expected "to continue through September, with momentum extending beyond September although at a more moderate level" [59], and on the anniversary "we will be comping quarters that have the GST impact, so the growth rate will moderate" [60]. Guidance already reflects it: after a 7.8% first quarter, the company guided the June quarter to 1.5% to 5.5% reported growth and the full year to the same range [61].

Consensus for 2026 sits at about $5.24 billion of revenue, roughly $201 million above 2025, from three contributing analysts. Holding India flat at its March-quarter run rate of $275.4 million for four quarters produces $1,101.6 million, or $212 million more than 2025 — more than the entire consensus increase, with no growth assumed anywhere else and none assumed in India beyond the level already achieved.

Following the 18 February 2026 fourth-quarter release, which paired the India record with the Ronaldo and Pro2col announcement [62], the shares rose from $16.54 to $19.57, up 18.3%. Following the 6 May 2026 first-quarter release, which paired a larger India beat with the increase in the GST cost estimate and a full-year range below the quarter's growth rate, the shares fell from $16.44 to $14.49, down 11.9%.

The exposure under the growth

India carries a tax dispute file that is not accrued: $109.7 million in aggregate at 31 March 2026, before interest and penalty adjustments, covering VAT and service tax assessments and five audited Indian income-tax years [63]. The itemisation sits with the rest of the group's assessment file in Consent Order and Claims. The company believes it is more likely than not to prevail and has accrued nothing, and it notes that "the Indian income tax authorities are auditing multiple years and it is uncertain whether additional assessments will be received" [64]. Two of the older assessments have already been won at the Tax Tribunal and appealed by the government to the High Court [65]. Against a market capitalisation near $1.26 billion, the unaccrued Indian file is a number worth carrying.

The disclosure architecture has not caught up with the revenue. China — $279.1 million of 2025 net sales, 5.5% of the total — is a separate reporting segment because it does not meet the criteria for aggregation [66], and it holds dedicated risk factors. India, at $889.6 million, sits inside the Asia Pacific region within the Primary Reporting Segment [67], and across the forty-two pages of Item 1A in the FY2025 Form 10-K, India is named twice — in a list of countries where contract manufacturers are located [68] and in a list of data-privacy statutes [69], neither of them about the market itself. The segmentation is defensible on its stated basis: China runs a different compensation model. The absence of a named India risk factor for a market approaching a fifth of revenue is a gap in the disclosure, and there is no India-level contribution margin anywhere in the corpus, so how profitable this growth is cannot be measured from the filings.

China is also the available base rate for what a concentrated Asian market can do in reverse. China net sales were $809.6 million in 2020 and $629.5 million in 2021 [70]; they were $279.1 million in 2025 [71]. Herbalife attributes the origin of that decline to a government action rather than to competition: the 2019 "100-day review" into the promotion and sale of health products "materially and adversely impacted our business in China in 2019 as Members significantly reduced activities and sales meetings during and following the Review" [72]. Six years later that market has not recovered; it fell a further 16% in local currency in the March 2026 quarter [73]. No comparable action is under way in India, and India's regulatory regime is not China's. The relevance is the shape of the risk, not a prediction: this company's largest market has been reset by a regulator once inside a decade, and India's 20.9% share of first-quarter 2026 net sales already exceeds the 14.6% China represented in 2020, the earliest year this corpus reaches.

What the evidence supports

The 2025–2026 return to growth is, in local-currency terms, mostly an India event — entirely so in the March 2026 quarter — and India's step-change is a government-funded price cut that Herbalife did not pay for and cannot repeat elsewhere without paying for it out of gross margin. The level benefit is durable — the rate "is not anticipated to change from this reduced rate" [74], so Indian shelf prices stay about 11% lower — but the growth-rate benefit annualises in September 2026, and the associated cost, now guided at $20–25 million a year, does not.

The strongest fact against this reading is that the tailwind is not the whole of India's momentum. Management dates the rebuild to distributor leadership training that predates the tax change [75], Asia Pacific new distributors grew 18% in the March quarter [76], and the quarter's ex-India local-currency softness was partly North American weather and shipment timing, without which North American net sales would have been slightly positive [77]. On a full-year basis, ex-India local-currency net sales in 2025 were up roughly 1%, not down.

Three checks would settle it, each a named line in a specific filing. India net sales in the December 2026 Form 10-K management discussion: at or above roughly $275 million for the quarter, the level has held through the anniversary rather than reverting to the pre-cut $210–225 million band. Ex-India local-currency net sales in the same filing, derived from the consolidated local-currency growth rate and the disclosed India local-currency growth rate: positive means the rest of the company has stopped shrinking. And the India GST net incremental cost line in 2027 guidance: a figure still rising with India's sales, against an unchanged treatment of the input credits in the contingencies note, would confirm that the cost side of this trade compounds with the revenue side.